Company

Hemedex, Inc., was founded in 2000 to commercialize a proprietary platform technology conceived at the Massachusetts Institute of Technology (MIT) to quantify tissue perfusion (i.e., blood flow at the capillary level).

This technology addresses the need for real-time, prognostic data in complex medical and surgical procedures.

These complex procedures often involve compromised vasculature, delayed ischemia, or other serious pathophysiology, resulting in high rates of morbidity, delayed recuperation, poor patient outcome and higher overall costs.

Hemedex’s patented technology can provide an early warning of impending tissue ischemia, help target appropriate therapies, and rapidly assess the effect of interventions on cerebral blood flow (CBF), thus providing clinicians with a powerful tool to enhance patient care.

The Bowman Perfusion Monitor® and QFlow500™ Perfusion Probe have FDA and Canadian clearance, are CE Marked and are distributed in 25 countries.

Hemedex is ISO 13485:2003 certified.

We invite you to explore our site to learn more about our unique technology solutions.

 

Vision

Our vision is to improve patient outcomes and reduce healthcare costs by providing insight for therapy.

 

Mission

Our mission is to elevate standards of care by delivering the most trusted and widely used tissue perfusion measurement devices available.

Next page »